PA8.F Paion AG

Oil, Gas & Consumable Fuels Frankfurt Exchange
6.48 EUR
Close of Feb 6, 2025
0.0120 0.2300
Market cap
EUR 46.2M
P/E
-
P/B
2.84x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2023.

Is PA8.F undervalued?

Graham number

The Graham number of Paion AG cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Paion AG fundamental analysis

No fundamental analysis for Paion AG yet.

Paion AG stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Paion AG

Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and intensive care medicine services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the trea…

Full company profile